Background stories of how others approached and experienced their European Horizon funding trajectory.
Published on | 7 months ago
Programmes HealthThe METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsPARSEC, funded under Horizon Europe Cluster 3 Call 'Advanced detection of threats and illicit goods in postal and express courier flows' aims to solve challenges facing eCommerce caused by threats and illicit goods in postal and express courier flows. The Flemish company CBRA Services coordinates the project.